↓ Skip to main content

Novel drugs for heart rate control in heart failure

Overview of attention for article published in Heart Failure Reviews, March 2018
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
32 Mendeley
citeulike
1 CiteULike
Title
Novel drugs for heart rate control in heart failure
Published in
Heart Failure Reviews, March 2018
DOI 10.1007/s10741-018-9696-x
Pubmed ID
Authors

Agata Bielecka-Dabrowa, Stephan von Haehling, Jacek Rysz, Maciej Banach

Abstract

In patients with heart failure, increased sympathetic activity is associated with a positive chronotropic stimulation leading to accelerated resting heart rate. Elevated heart rate (HR) is a risk factor for cardiovascular events, both in the general population and in patients with heart failure. Ivabradine is a pure HR-lowering agent, and it does not affect myocardial contractility, blood pressure, intracardiac conduction, or ventricular repolarization. In clinical trials such as BEAUTIFUL, CARVIVA HF, SHIFT, and INTENSIFY in patients with systolic left ventricular dysfunction, heart rate reduction with ivabradine brought positive outcomes. However, the results of the recent meta-analysis are rather neutral. In a diabetes mouse model of heart failure with preserved ejection fraction (HFpEF), selective heart rate reduction by Ifinhibition improved vascular stiffness, left ventricular (LV) contractility, and diastolic function. However, EDIFY (Effect of ivabradine in patients with heart rate with preserved ejection fraction) trial show that the use of ivabradine in patients with HFpEF is not supported. The further clinical trials investigating the use of ivabradine in heart failure should be carried out.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 32 100%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 5 16%
Student > Bachelor 4 13%
Student > Postgraduate 2 6%
Professor 2 6%
Lecturer 1 3%
Other 3 9%
Unknown 15 47%
Readers by discipline Count As %
Medicine and Dentistry 7 22%
Nursing and Health Professions 2 6%
Agricultural and Biological Sciences 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Social Sciences 1 3%
Other 3 9%
Unknown 17 53%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 December 2023.
All research outputs
#19,603,915
of 24,969,131 outputs
Outputs from Heart Failure Reviews
#593
of 739 outputs
Outputs of similar age
#246,789
of 335,242 outputs
Outputs of similar age from Heart Failure Reviews
#10
of 13 outputs
Altmetric has tracked 24,969,131 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 739 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one is in the 17th percentile – i.e., 17% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 335,242 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.